Home » Stocks » Harpoon Therapeutics

Harpoon Therapeutics, Inc. (HARP)

Stock Price: $15.31 USD 0.23 (1.53%)
Updated Oct 27, 2020 1:14 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 384.92M
Revenue (ttm) 9.71M
Net Income (ttm) -55.42M
Shares Out 25.14M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $15.31
Previous Close $15.08
Change ($) 0.23
Change (%) 1.53%
Day's Open 15.10
Day's Range 14.94 - 15.56
Day's Volume 17,148
52-Week Range 10.27 - 25.02

More Stats

Market Cap 384.92M
Enterprise Value 227.67M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.14M
Float 14.88M
EPS (basic) -2.28
EPS (diluted) -2.27
FCF / Share 1.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 10.45%
Payout Ratio n/a
Shares Short 880,585
Short Ratio 3.31
Short % of Float 5.92%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 9.57
PS Ratio 39.64
PB Ratio 5.25
Revenue 9.71M
Operating Income -57.68M
Net Income -55.42M
Free Cash Flow 40.24M
Net Cash 157.25M
Net Cash / Share 6.25
Gross Margin -368.85%
Operating Margin -594.02%
Profit Margin -570.80%
FCF Margin 414.43%
ROA -20.35%
ROE -57.02%
ROIC -52.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 8
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(103.92% upside)
Current: $15.31
Target: 31.22
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth21.62%570.9%--
Gross Profit5.784.750.71-
Operating Income-58.25-27.76-16.62-11.15
Net Income-55.57-27.37-16.83-11.41
Shares Outstanding21.751.070.890.53
Earnings Per Share-2.56-25.65-18.81-21.61
Operating Cash Flow-2.89-27.131.71-10.79
Capital Expenditures-3.52-0.66-2.28-0.55
Free Cash Flow-6.41-27.79-0.56-11.35
Cash & Equivalents14889.4929.427.74
Total Debt14.94--2.31
Net Cash / Debt13389.4929.425.42
Book Value94.22-53.48-26.94-10.44
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Harpoon Therapeutics, Inc.
Country United States
Employees 76
CEO Gerald McMahon

Stock Information

Ticker Symbol HARP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: HARP
IPO Date February 8, 2019


Harpoon Therapeutics, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.